Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ALZHEIMER'S AND PARKINSON'S DISEASES
A Global Strategic Business Report

This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, & Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 87 companies including many key and niche players worldwide such as Boehringer Ingelheim, Bristol-Myers Squibb Co., Eisai Inc., Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Novartis AG, Ortho-McNeil Neurologics, Inc., Pfizer Inc., Roche, Shire Pharmaceuticals Group PLC, and Valeant Pharmaceuticals International. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1704  PAGES:    451
PRICE:    $3950  DATE:       May 2008
COMPANIES:  87  MARKET DATA TABLES:   171
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ALZHEIMER'S AND PARKINSON'S DISEASES (Complete Report) Pages : 451   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS5$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Product Segments.....I-3
Anti-Alzheimer’s Disease Drugs.....I-3
Cholinesterase Inhibitors.....I-3
  
   NMDARA.....I-4
Anti-Parkinson’s Disease Drugs.....I-4
Dopaminergic Agents (Levodopa/Carbidopa).....I-4
Dopamine Agonists.....I-4
  
   Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine
  Amplifiers).....I-5
COMT Inhibitors.....I-5
MAO-B Inhibitors.....I-5
Dopamine Amplifiers.....I-5
  
II. EXECUTIVE SUMMARY83$2250
  1. Outlook.....II-11 $100  
   Current and Future Analysis.....II-1
1$100
  2. Neurodegenerative Diseases Market – A Brief Overview.....II-24 $400  
   Key Brands in NDD Market.....II-2 1$100
   Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart).....II-3
Factors Affecting Market.....II-3
Major Growth Drivers.....II-3
Major Growth Inhibitors.....II-3
1$350
   Market Trends.....II-4
High Prevalence Rates Drive Market Growth.....II-4
Rapid Growth of Ageing Population.....II-4
Price Hikes and Government Caps.....II-4
1$100
   Combination Therapy Gaining Ground.....II-5
Research & Development.....II-5
Future Holds Promise.....II-5
1$100
  3. Alzheimer’s Market Overview.....II-613 $1300  
   A Peek at Anti-AD Drug Market.....II-6
Impact of Dementia.....II-6
Epidemiology.....II-6
1$100
   Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart).....II-71$350
   Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart).....II-8

Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart).....II-8
Patient Growth Drivers.....II-8
Demographics Spell Opportunities.....II-8
1$350
   High Growth Rates for AD Drugs.....II-9
The Impact of Aricept.....II-9
Epic of NMDARA.....II-9
1$100
   Strengths.....II-10
Weaknesses.....II-10
1$100
   Future Therapies.....II-11
How Successful will the Late Stage Therapies be?.....II-11
A Geographic Milieu.....II-11
US.....II-11
Europe.....II-11
Japan.....II-11
1$100
   Alternative Drug Delivery Technologies Gaining Ground.....II-12
Transdermal Patch.....II-12
Domination of Acetyl Cholinesterase Inhibitors.....II-12
Dramatic Changes in Market Lie Ahead.....II-12
Advances in Next-Generation Treatments.....II-12
1$100
   Beta Amyloid Hypothesis.....II-13
Growth Drivers.....II-13
Ageing Baby Boomers Drive AD Market.....II-13
Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart).....II-13
1$350
   New Hypothesis Enables Effective Treatment.....II-14
Unmet Medical Needs Drive Market Growth.....II-14
Growth Inhibitors.....II-14
Link with Other Aliments.....II-14
Misdiagnosis.....II-14
Patient Awareness.....II-14
Medical Refunds.....II-14
1$100
   Competitive Landscape.....II-15
Pharmaceutical Majors Rule the Market.....II-15
Eisai/Pfizer.....II-15
Novartis.....II-15
Shire/Johnson & Johnson.....II-15
1$100
   Lundbeck/Forest.....II-16
Ipsen and UCB.....II-16
Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart).....II-16
1$350
   Year of Approval of AD Drugs in Leading Countries.....II-17
Compounds in Pipeline.....II-17
1$100
   Outlook for AD Drugs Market.....II-18
1$100
  4. Parkinson’s Disease Market Overview.....II-194 $400  
   An Alluring Market.....II-19
Prevalence.....II-19
Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart).....II-19
1$350
   Current Treatments.....II-20
New Medicines on the Horizon.....II-20
New Findings.....II-20
Product Launches Through 2009.....II-20
Dominance of Dopamine Agonists.....II-20
1$100
   Revival Revels in Other Anti-PD Drugs Segment.....II-21
COMT Inhibitors Growing Fastest.....II-21
Key Market Drivers.....II-21
Rising Awareness Magnifies Patient Base.....II-21
Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth.....II-21
The Debut of Stalevo.....II-21
Unmet Clinical Needs Show Mammoth Prospects.....II-21
1$100
   Key Market Inhibitors.....II-22
Limitations of Existing Medicines Inhibit Market Growth.....II-22
Under-Diagnosis Restrains Market Potential.....II-22
Generic Competition from L-Dopa and Carbidopa Curbs Market Growth.....II-22
Restricted Term of Dopamine Agonists Usage Delays Market Growth.....II-22
1$100
  5. Disease Overview.....II-233 $300  
   Alzheimer's Disease.....II-23
Definition.....II-23
The Cause.....II-23
Finding AD.....II-23
Prevention.....II-23
1$100
   Treatment.....II-24
Parkinson’s Disease.....II-24
Definition.....II-24
Pathophysiology.....II-24
1$100
   Diagnosis.....II-25
Prevalence.....II-25
Treatment.....II-25
Surgical Intervention.....II-25
1$100
  6. Drug Classification.....II-267 $500  
   Anti-Alzheimer’s’ Disease Drugs.....II-26
NMDARA.....II-26
1$100
   Memantine.....II-27
Cholinesterase Inhibitors (ChEIs).....II-27
Donepezil (Aricept).....II-27
Rivastigmine (Exelon).....II-27
1$100
   Galantamine Hydrobromide (Razadyne).....II-28
Tacrine (Cognex).....II-28
Other Alternatives.....II-28
Vitamin E.....II-28
Estrogen Therapy.....II-28
1$100
   Anti-Inflammatory Drugs.....II-29
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).....II-29
Antioxidants.....II-29
Vaccine.....II-29
Gingko Biloba.....II-29
Pure Medical Nicotine.....II-29
Anti-Parkinson’s Disease Drugs.....II-29
1$100
   Dopaminergic agents.....II-30
Levodopa/Carbidopa.....II-30
Dopamine Agonists.....II-30
Pergolide/Permax.....II-30
Bromocriptine/Parlodel.....II-30
Ropinirole/Requip.....II-30
1$100
   Pramipexole/Mirapex.....II-31
Cabergoline/Dostinex.....II-31
Apomorphine/Apokyn.....II-31
Other Dopamine Agonists.....II-31
Other PD Drugs.....II-31
COMT Inhibitors.....II-31
Tolcapone (Tasmar).....II-31
1$100
   Entacapone (Comtan).....II-32
MAO-B Inhibitors.....II-32
Dopamine Amplifiers.....II-32
Anticholinergics.....II-32
1$100
  7. Future Therapies.....II-334 $400  
   Alzheimer’s Disease.....II-33
Key Pipeline Products.....II-33
Phenserine.....II-33
Ropern.....II-33
1$100
   Alzhemed.....II-34
MEM 1003.....II-34
Ampakine Compounds.....II-34
Parkinson’s Disease.....II-34
Key Pipeline Products.....II-34
1$100
   Adenosine A2a Antagonist.....II-35
Spheramine®.....II-35
Safinamide.....II-35
1$100
   O-1369.....II-36
1$100
  8. New Findings.....II-374 $400  
   Risedronate Minimizes Risk of Hip Fractures in PD Patients.....II-37
Researchers Identify New Genes Responsible for AD.....II-37
Researchers Establish a New Link Between Loneliness and AD.....II-37
Researchers Try to Identify Early Stages of AD.....II-37
1$100
   SORL1 – The New Gene Found to be Responsible for AD.....II-38
Scientists Conduct Research Work on CERE-120 Gene Therapy.....II-38
Researchers Find New Snail Toxin for Nervous System Disorders.....II-38
Researchers Study Anti-PD Properties of Nicotine.....II-38
Researchers Establish New Link Between Pesticides and PD.....II-38
1$100
   Study Relates AD to the Quantity of Amyloid Protein.....II-39
Researchers Establish Effectiveness of Gene Therapy on AD Patients.....II-39
Scientists Use Electric Current to Treat PD Patients.....II-39
Scientists Prove Earlier Assumptions Wrong.....II-39
1$100
   Scientists Discover 2 Distinct Types of MCIs.....II-40
1$100
  9. Recent Industry Activity.....II-4112 $800  
   Eisai Acquires MGI Pharma.....II-41
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Disease Treatment.....II-41
Merz Licenses Anti-Alzheimer’s Drug Technology from TAU.....II-41
Eisai Acquires Morphotek.....II-41
Transition Therapeutics Acquires NeuroMedix.....II-41
Evotec Teams Up with Boehringer Ingelheim.....II-41
1$100
   Siemens Signs Partnership Agreement with Wyeth.....II-42
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker.....II-42
Pfizer Joins Forces with Genizon.....II-42
Intellect Signs Licensing Agreement with IBL.....II-42
Boehringer Ingelheim signs R&D agreement with Ablynx.....II-42
1$100
   Avicena Teams Up with NINDS for Phase III Trial of PD-02.....II-43
Prana Begins Phase II clinical trial for PBT2.....II-43
Idera Teams Up with Merck.....II-43
1$100
   Merck Signs R&D Agreement with Neuroptix.....II-44
Neuro-Hitech Takes Over Q-RNA.....II-44
Neurogen Inks Licensing Agreement with Wyeth.....II-44
Acumen Revises License Agreement with Merck.....II-44
Newron Begins 2nd Phase III clinical trial for Safinamide.....II-44
1$100
   Newron Inks Global Licensing Agreement with Serono.....II-45
Pfizer Inks License Agreement with TransTech.....II-45
CeNeS Renews R&D Agreement with Tripos.....II-45
Athenagen Acquires Zapaq.....II-45
Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591.....II-45
1$100
   Teva Receives Health Canada Clearance for Azilect.....II-46
Valeant Introduces Zelapar Anti-PD Tablets in the US.....II-46
Merck to Halt Further Development of Anti-PD Drug Called Sarizotan.....II-46
Amarin Obtains Global Rights for New Apomorphine Formulation.....II-46
FDA Clears Exelon for Parkinson's Disease.....II-46
1$100
   Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112.....II-47
Pfizer Takes Over Rinat.....II-47
TorreyPines Begins 2nd Phase-I clinical trial for NGX267.....II-47
Kyowa Hakko Inks Licensing Agreement with Britannia.....II-47
Schwarz Pharma Receives EMEA Clearance for Neupro.....II-47
1$100
   Evotec Inks Licensing Agreement with Roche.....II-48
RheoGene Receives Funds from MJFF.....II-48
Eisai Initiates Phase I clinical trial for E2012.....II-48
Apokyn(R) Receives Approval in North America.....II-48
FDA Approves Azilect.....II-48
1$100
   Voyager Completes Phase II Study for of Leuprolide Acetate.....II-49
New Discovery for the Treatment of Alzheimer's Disease in Canada.....II-49
Ortho-McNeil Launches Razadyne™ ER.....II-49
1$100
   Flurizan Enters Phase II Clinical Trials.....II-50
Axonyx Releases Supplementary Results of Phase III Trial for Phenserine.....II-50
Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist.....II-50
BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinson's Animal
  Models.....II-50
1$100
   Predix’s PRX-03140 Completes First Clinical Trial in Alzheimer's Disease.....II-51
Galapagos and Senexis Expand Collaboration.....II-51
Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch.....II-51
Neurologix Posts Interim Results of Phase I Gene Therapy.....II-51
GB Therapeutics Receives License for CHF1512.....II-51
Alzhemed™ Begins Phase III Trials.....II-51
1$100
   Newron Commences Phase III Trial With Safinamide.....II-52
Ceregene Bags FDA Approval for Gene Therapy Alzheimer's Study.....II-52
Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s.....II-52
FDA Grants Fast Track Designation.....II-52
Ester Neurosciences Joins Forces with Pharmacopeia.....II-52
1$100
  10. Focus on Select Players.....II-535 $500  
   Boehringer Ingelheim (Germany).....II-53
Bristol-Myers Squibb Co. (USA).....II-53
Eisai Inc. (USA).....II-53
1$100
   Eli Lilly and Company (USA).....II-54
Forest Pharmaceuticals (USA).....II-54
GlaxoSmithKline PLC (UK).....II-54
1$100
   H. Lundbeck A/S (Denmark).....II-55
Merz Pharmaceuticals GMBH (Germany).....II-55
Novartis AG (Switzerland).....II-55
1$100
   Ortho-McNeil Neurologics, Inc. (USA).....II-56
Pfizer Inc (US).....II-56
Roche (Switzerland).....II-56
Shire Pharmaceuticals Group PLC (UK).....II-56
1$100
   Valeant Pharmaceuticals International (USA).....II-57
1$100
  11. Global Market Perspective.....II-58   
   Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-581$350
   Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-601$350
   Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-611$350
   Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-621$350
   Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment –Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-63

Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment –Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-63
1$350
   Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-64

Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012.....II-64
1$350
   Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-651$350
   Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-661$350
   Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-671$350
   Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart).....II-681$350
   Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-691$350
   Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart).....II-701$350
   Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-711$350
   Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-721$350
   Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment – Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-73

Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment – Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-73
1$350
   Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-74

Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-74
1$350
   Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-751$350
   Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-761$350
   Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-771$350
   Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-781$350
   Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-791$350
   Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-801$350
   Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-811$350
   Table 36: World Long-term Projections for Other PD Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-821$350
   Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-831$350
III. MARKET71$1950
  1. The United States.....III-120 $1325  
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
AD Market Overview.....III-1
Approval of Cholinesterase Inhibitors for MCI to Drive Market.....III-1
1$75
   Competitive Landscape.....III-2
Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart).....III-2
1$200
   Status of AD Drugs.....III-3
New Products in Clinical Trails.....III-3
1$75
   Prevalence.....III-4
Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart).....III-4
PD Therapies Market.....III-4
Levodopa/Carbidopa on Declining Spree.....III-4
Competition.....III-4
1$200
   Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart).....III-5
Patent Expiry Status.....III-5
Patent Expiry Status of Parkinson’s Disease Drugs in the US.....III-5
1$200
   New Brands and Pipeline Analysis.....III-6
PD Prevalence.....III-6
New Findings.....III-6
2$150
   Strategic Corporate Developments.....III-87$525
   Key Players.....III-153$225
   B. Market Analytics.....III-18
Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-18
1$200
   Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-191$200
   Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-20
1$200
  2. Canada.....III-214 $425  
   A. Market Analysis.....III-21
Current & Future Analysis.....III-21
Prevalence.....III-21
Strategic Corporate Developments.....III-21
1$75
   B. Market Analytics.....III-22
Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22
1$200
   Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-231$200
   Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-24
1$200
  3. Japan.....III-254 $425  
   A. Market Analysis.....III-25
Current & Future Analysis.....III-25
Prevalence.....III-25
Strategic Corporate Developments.....III-25
1$75
   B. Market Analytics.....III-26
Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-26
1$200
   Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-271$200
   Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-28
1$200
  4. Europe.....III-299 $1075  
   A. Market Analysis.....III-29
Current & Future Analysis.....III-29
Prevalence.....III-29
Alzheimer’s Disease.....III-29
1$75
   Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart).....III-30
Parkinson’s Disease.....III-30
Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart).....III-30
1$200
   Competitive Scenario.....III-31
Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart).....III-31
Strategic Corporate Developments.....III-31
1$200
   B. Market Analytics.....III-32
Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-32
1$200
   Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-331$200
   Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-341$200
   Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-351$200
   Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-361$200
   Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-37
1$200
  4a. Germany.....III-385 $525  
   A. Market Analysis.....III-38
Current & Future Analysis.....III-38
Prevalence.....III-38
Strategic Corporate Developments.....III-38
1$75
   Key Players.....III-391$75
   B. Market Analytics.....III-40
Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-40
1$200
   Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-42
1$200
  4b. France.....III-434 $450  
   A. Market Analysis.....III-43
Current & Future Analysis.....III-43
Prevalence.....III-43
1$75
   B. Market Analytics.....III-44
Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-44
1$200
   Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-451$200
   Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-46
1$200
  4c. United Kingdom.....III-476 $525  
   A. Market Analysis.....III-47
Current & Future Analysis.....III-47
Prevalence.....III-47
New Findings.....III-47
1$75
   Strategic Corporate Developments.....III-48
Key Players.....III-48
2$150
   B. Market Analytics.....III-50
Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-50
1$200
   Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-511$200
   Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$200
  4d. Italy.....III-534 $425  
   A. Market Analysis.....III-53
Current & Future Analysis.....III-53
Prevalence.....III-53
Strategic Corporate Developments.....III-53
1$75
   B. Market Analytics.....III-54
Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-54
1$200
   Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-551$200
   Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-56
1$200
  4e. Spain.....III-574 $425  
   A. Market Analysis.....III-57
Current & Future Analysis.....III-57
Prevalence.....III-57
1$75
   B. Market Analytics.....III-58
Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-58
1$200
   Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-591$200
   Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-60
1$200
  4f. Rest of Europe.....III-616 $575  
   A. Market Analysis.....III-61
Current & Future Analysis.....III-61
Prevalence.....III-61
New Findings.....III-61
Strategic Corporate Developments.....III-61
1$75
   Key Players.....III-622$150
   B. Market Analytics.....III-64
Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-64
1$200
   Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-651$200
   Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-66
1$200
  5. Rest of World.....III-675 $750  
   A. Market Analysis.....III-67
Current & Future Analysis.....III-67
Prevalence.....III-67
Strategic Corporate Developments.....III-67
2$150
   B. Market Analytics.....III-69
Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-69
1$200
   Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment – Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-701$200
   Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment – Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-711$200
IV. COMPETITIVE LANDSCAPE 279$995
  
Total Companies Profiled: 87 (including Divisions/Subsidiaries - 105)

Region/Country                 Players

The United States                 51
Canada                             5
Japan                              3
Europe                            36 
     France                        1
     Germany                       9
     The United Kingdom           11
     Italy                         2
     Spain                         3
     Rest of Europe               10 
Asia-Pacific (Excluding Japan)     5
Middle East                        5
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.